why choose us

First received: October 28, 2022

Clinical Trial: A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Pancreatic Cancer

Study Type: INTERVENTIONAL


Official Title: A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Brief Summary: The purpose of this study is to evaluate the safety and clinical activity of tadalafil, pembrolizumab, ipilimumab, and CRS-207 in subjects with metastatic pancreatic adenocarcinoma who have progressed after at least 1 prior chemotherapy regimen.

Read more